


or a pharmaceutically acceptable salt, solid form, solvate, hydrate, stereoisomer, tautomer or racemic mixture thereof.

[0010d] In another aspect, there is provided use of a compound in the manufacture of a medicament for improvement of the modified Rodnan skin score of a patient having scleroderma, reduction or improvement of the skin thickness of a patient having scleroderma, reduction or improvement of skin induration of a patient having scleroderma, improvement of the pulmonary function of a patient having scleroderma, improvement of the dermatology quality of life index of a patient having scleroderma, improvement of the carbon monoxide diffusing capacity of a patient having scleroderma, improvement of the Mahler Dyspnea index of a patient having scleroderma, improvement of the Saint George's Respiratory Questionnaire score of a patient having scleroderma, improvement of the UCLA scleroderma clinical trial consortium gastrointestinal tract score of a patient having scleroderma, improvement of flow-mediated dilatation or improvement or increase of the six minute walk distance of a patient having scleroderma, wherein the compound is a compound of formula I:




I,

or a pharmaceutically acceptable salt, solid form, solvate, hydrate, stereoisomer, tautomer or racemic mixture thereof.

What is claimed is:

1. Use of a compound for the manufacture of a medicament for the treatment, prevention or management of an immune-related disease or an inflammatory disease, wherein the compound is a compound of formula I




I,

or a pharmaceutically acceptable salt, solid form, solvate, hydrate, stereoisomer, tautomer or racemic mixture thereof, wherein the disease is lupus, scleroderma, lupus pernio, sarcoidosis, Sjögren syndrome, ANCA-induced vasculitis, anti-phospholipid syndrome, or myasthenia gravis.

2. The use of claim 1, wherein the compound is (*S*)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione or a pharmaceutically acceptable salt, solid form, solvate, hydrate, or tautomer thereof.
3. The use of claim 1, wherein the compound is (*S*)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione.
4. The use of claim 1, wherein the compound is (*S*)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione hydrochloride.
5. The use of any one of claims 1-4, wherein the disease is systemic lupus erythematosus, cutaneous lupus erythematosus, scleroderma, lupus pernio or sarcoidosis.
6. The use of claim 5, wherein the disease is systemic lupus erythematosus.
7. The use of claim 6, wherein the disease is severe systemic lupus erythematosus.
8. The use of claim 5, wherein the disease is cutaneous lupus erythematosus
9. The use of claim 5, wherein the disease is scleroderma.
10. The use of claim 9, wherein the scleroderma is localized, systemic, limited or diffuse scleroderma.
11. The use of claim 10, wherein the systemic scleroderma comprises CREST syndrome.


12. Use of a compound for the manufacture of a medicament for the reduction, inhibition or prevention of a symptom of systemic lupus erythematosus, wherein the symptom is selected from the group consisting of joint pain, joint swelling, arthritis, chest pain when taking a deep breath, fatigue, fever with no other cause, general discomfort, uneasiness, hair loss, mouth sores, swollen lymph nodes, sensitivity to sunlight, skin rash, headaches, numbness, tingling, seizures, vision problems, personality changes, abdominal pain, nausea, vomiting, abnormal heart rhythms, coughing up blood and difficulty breathing, patchy skin color and Raynaud's phenomenon, and wherein the compound is a compound of formula I



I,

or a pharmaceutically acceptable salt, solid form, solvate, hydrate, stereoisomer, tautomer or racemic mixture thereof.


13. Use of a compound for the manufacture of a medicament for the reduction, inhibition or prevention of a symptom of scleroderma, wherein the symptom is selected from the group consisting of (i) gradual hardening, thickening, and tightening of the skin; (ii) skin discoloration; (iii) numbness of extremities; (iv) shiny skin; (v) small white lumps under the surface of the skin that erupt into a chalky white fluid; (vi) Raynaud's esophageal dysfunction; (vii) telangiectasia; (viii) pain and/or stiffness of the joints; (ix) swelling of the hands and feet; (x) itching of the skin; (xi) stiffening and curling of the fingers; (xii) ulcers on the outside of knuckles and elbows; (xiii) heartburn, difficulty in swallowing, diarrhea, irritable bowel, and constipation; (xiv) fatigue and weakness; (xv) shortness of breath; (xvi) arthritis; (xvii) hair loss; (xviii) internal organ problems; (xix) digital ulcers; and (xx) digital auto-amputation, and wherein the compound is a compound of formula I



I,

or a pharmaceutically acceptable salt, solid form, solvate, hydrate, stereoisomer, tautomer or racemic mixture thereof.

14. Use of a compound for the manufacture of a medicament for improvement of the modified Rodnan skin score of a patient having scleroderma, reduction or improvement of the skin thickness of a patient having scleroderma, reduction or improvement of skin induration of a patient having scleroderma, improvement of the pulmonary function of a patient having scleroderma, improvement of the dermatology quality of life index of a patient having scleroderma, improvement of the carbon monoxide diffusing capacity of a patient having scleroderma, improvement of the Mahler Dyspnea index of a patient having scleroderma, improvement of the Saint George's Respiratory Questionnaire score of a patient having scleroderma, improvement of the UCLA scleroderma clinical trial consortium gastrointestinal tract score of a patient having scleroderma, improvement of flow-mediated dilatation of a patient having scleroderma, or improvement or increase of the six minute walk distance of a patient having scleroderma, wherein the compound is a compound of formula I:



I,

or a pharmaceutically acceptable salt, solid form, solvate, hydrate, stereoisomer, tautomer or racemic mixture thereof.

15. The use of any one of claims 12-14, wherein the compound is (*S*)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione or a pharmaceutically acceptable salt, solid form, solvate, hydrate or tautomer thereof.

16. The use of any one of claims 12-14, wherein the compound is (*S*)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione.

17. The use of any one of claims 12-14, wherein the compound is (*S*)-3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisindolin-2-yl)piperidine-2,6-dione hydrochloride.

18. The use of any one of claims 1-17, wherein the medicament is to be administered in combination with a second active agent, which is an anti-inflammatory or immunomodulatory compound.
19. The use of any one of claims 1-18, wherein the effective amount of the compound I is about 0.005 mg/kg to about 10 mg/kg of the patient's body weight.